These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 28847261)

  • 21. Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial.
    Yaniv E; Preis M; Hadar T; Shvero J; Haddad M
    Laryngoscope; 2009 Feb; 119(2):284-8. PubMed ID: 19160429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brief report: treatment of bleeding in hereditary hemorrhagic telangiectasia with aminocaproic acid.
    Saba HI; Morelli GA; Logrono LA
    N Engl J Med; 1994 Jun; 330(25):1789-90. PubMed ID: 8190155
    [No Abstract]   [Full Text] [Related]  

  • 23. Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.
    Kochanowski J; Sobieszczańska M; Tubek S; Żurek M; Pawełczak J
    Hum Vaccin Immunother; 2015; 11(3):680-1. PubMed ID: 25839219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topical timolol for the treatment of epistaxis in hereditary hemorrhagic telangiectasia.
    Olitsky SE
    Am J Otolaryngol; 2012; 33(3):375-6. PubMed ID: 22079094
    [No Abstract]   [Full Text] [Related]  

  • 25. Bevacizumab as a treatment for hereditary hemorrhagic telangiectasia in children: a case report.
    Ospina FE; Echeverri A; Posso-Osorio I; Jaimes L; Gutierrez J; Tobón GJ
    Colomb Med (Cali); 2017 Jun; 48(2):88-93. PubMed ID: 29021642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tranexamic acid in hereditary hemorrhagic telangiectasia.
    Lozano M
    N Engl J Med; 2002 Feb; 346(6):457. PubMed ID: 11832543
    [No Abstract]   [Full Text] [Related]  

  • 27. Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia: An Evidence-based Review.
    Halderman AA; Ryan MW; Marple BF; Sindwani R; Reh DD; Poetker DM
    Am J Rhinol Allergy; 2018 Jul; 32(4):258-268. PubMed ID: 29745243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.
    Chen S; Karnezis T; Davidson TM
    Laryngoscope; 2011 Mar; 121(3):644-6. PubMed ID: 21344447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.
    Karnezis TT; Davidson TM
    Laryngoscope; 2011 Mar; 121(3):636-8. PubMed ID: 21344445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of propranolol for epistaxis in hereditary haemorrhagic telangiectasia: retrospective, then prospective study, in a total of 21 patients.
    Contis A; Gensous N; Viallard JF; Goizet C; Léauté-Labrèze C; Duffau P
    Clin Otolaryngol; 2017 Aug; 42(4):911-917. PubMed ID: 28032956
    [No Abstract]   [Full Text] [Related]  

  • 31. Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia.
    Brinkerhoff BT; Poetker DM; Choong NW
    N Engl J Med; 2011 Feb; 364(7):688-9. PubMed ID: 21323562
    [No Abstract]   [Full Text] [Related]  

  • 32. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.
    Dupuis-Girod S; Ginon I; Saurin JC; Marion D; Guillot E; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Lorcerie B; Rivière S; Corre R; Giraud S; Bailly S; Paintaud G; Ternant D; Valette PJ; Plauchu H; Faure F
    JAMA; 2012 Mar; 307(9):948-55. PubMed ID: 22396517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hemorrhagic telangiectasia.
    Ananthasubramaniam G; Sathyavathi R; Chitra N
    J Assoc Physicians India; 1981 May; 29(5):425-7. PubMed ID: 7298565
    [No Abstract]   [Full Text] [Related]  

  • 34. Thalidomide for Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia: A Preliminary Study.
    Fang J; Chen X; Zhu B; Ye H; Zhang W; Guan J; Su K
    Otolaryngol Head Neck Surg; 2017 Aug; 157(2):217-221. PubMed ID: 28418273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study.
    Geisthoff UW; Seyfert UT; Kübler M; Bieg B; Plinkert PK; König J
    Thromb Res; 2014 Sep; 134(3):565-71. PubMed ID: 25005464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy of tranexamic acid in a patient with hereditary hemorrhagic telangiectasia and massive epistaxis].
    Pérez del Molino A; Zarrabeitia R; Fernández A; Botella LM
    Med Clin (Barc); 2004 Jun; 123(3):118-9. PubMed ID: 15225479
    [No Abstract]   [Full Text] [Related]  

  • 37. In reference to hereditary hemorrhagic telangiectasia/avastin.
    Bachmann-Harildstad G
    Laryngoscope; 2010 Oct; 120(10):2134. PubMed ID: 20824638
    [No Abstract]   [Full Text] [Related]  

  • 38. Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT).
    Chavan A; Schumann-Binarsch S; Luthe L; Nickau B; Elsässer A; Kühnel T; Geisthoff U; Köhne H
    Vasa; 2013 Mar; 42(2):106-10. PubMed ID: 23485837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intranasal topical estrogen in the management of epistaxis in hereditary hemorrhagic telangiectasia.
    Minami K; Haji T
    Acta Otolaryngol; 2016; 136(5):528-31. PubMed ID: 26808464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low dose of bevacizumab is safe and effective in preventing bleeding episodes in hereditary hemorrhagic telangiectasia.
    Lazaraki G; Akriviadis E; Pilpilidis I; Parisi I; Tzilves D; Tarpangos A
    Am J Gastroenterol; 2011 Dec; 106(12):2204-6. PubMed ID: 22138950
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.